Prediction of Amyloid‐Beta PET Status with a Combination of Digital Clock and Recall, Digital Trail Making Test‐Part B, and Blood‐Based Biomarkers

A multimodal model based on DCR, dTMT-B, ±APOE, and various BBMs had excellent performance in predicting Aβ-PET status, at levels comparable to CSF biomarkers of AD. ML-enabled digital cognitive assessments that leverage process-based metrics, such as the DCR and dTMT-B, enable cost-effective integration into clinical workflows to identify patients who are most likely to have Aβ+ PET status, allowing for prioritizing the most suitable candidates for DMTs.